Related Experiment Videos
Changes in temporal patterns of local failure after breast-conserving therapy and their prognostic implications
Daniel J Krauss1, Larry L Kestin, Christina Mitchell
1Department of Radiation Oncology, William Beaumont Hospital, 3601 W. 13 Mile Road, Royal Oak, MI 48072, USA.
International Journal of Radiation Oncology, Biology, Physics
|October 7, 2004
Summary
Ipsilateral breast tumor recurrence (IBTR) rates change over time, with elsewhere failures becoming more common after five years. Time to recurrence is the key factor for prognosis after IBTR.
Area of Science:
- Oncology
- Radiation Oncology
- Surgical Oncology
Background:
- Breast cancer treatment often involves conservative surgery (CS) and radiation therapy (RT).
- Understanding recurrence patterns is crucial for optimizing patient outcomes.
- Ipsilateral breast tumor recurrence (IBTR) and contralateral breast failure (CL) are important endpoints.
Purpose of the Study:
- To analyze the temporal patterns and rates of IBTR based on failure type: true recurrence/marginal miss (TR/MM) versus elsewhere (E).
- To compare IBTR rates with contralateral failure (CL) rates in Stage I/II breast cancer patients treated with CS and RT.
- To identify prognostic factors for survival after recurrence.
Main Methods:
- Analysis of 1448 patients with Stage I/II invasive breast carcinoma treated with CS and RT (median dose >60 Gy) between 1980-1997.
- Categorization of IBTRs into TR/MM (same quadrant) and E (remote from index lesion).
- Evaluation of temporal recurrence patterns and correlation with CL failure rates over a median follow-up of 8.5 years.
Main Results:
- Overall 5-, 10-, and 15-year actuarial rates were 2%, 7%, 10% for IBTR and 4%, 9%, 12% for CL.
- TR/MM constituted 74.7% of IBTRs, while E failures accounted for 25.3%.
- E failures increased in proportion to total IBTRs after 5 years (7% at 0-5 years to 39% at 5-10 years). Contralateral failure was more common in the first 5 years (p=0.02).
Conclusions:
- IBTR rates and patterns evolve over time, with E failures becoming increasingly significant after 5 years.
- After 5 years, IBTR rates approach those of contralateral breast cancer development.
- Time to tumor recurrence is the most significant predictor of prognosis following IBTR.